Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Ripretinib vs Sunitinib for Gastrointestinal Stromal Tumor
Recruiting2 awardsPhase 3
Seattle, Washington
This trial compares a new drug (ripretinib) to an existing one (sunitinib) to treat people with GIST who have progressed on a previous drug. Participants may switch to ripretinib if disease progresses.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service